Voyager Therapeutics, Inc.

$5.76 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc. is a gene therapy company, which is focused on developing treatments and platform technologies. Its gene therapy platforms enable it to engineer, optimize, manufacture, and deliver its adeno-associated virus (AAV)-based gene therapies. It is identifying AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. It has developed a AAV capsid discovery platform, Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) to facilitate the selection of AAV capsids with blood brain barrier (BBB) crossing and cell-specific transduction properties for therapeutic applications. Its gene therapy programs include treatment programs for Huntington's disease, monogenic amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and various diseases linked to GBA1 mutations, including Parkinson's disease, Lewy body dementia and Gaucher's disease. It also focuses on tauopathies and indications in neuro-oncology.

Stock Analysis

last close $5.84
1-mo return -4.7%
3-mo return -35.6%
avg daily vol. 339.13T
52-week high 10.6
52-week low 2.46
market cap. $192M
forward pe -
annual div. -
roe -66.8%
ltg forecast -
dividend yield -
annual rev. $32M
inst own. 58.5%

Subscribe now for daily local and international financial news